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levels. Ten endpoints were measured, including oxygen 
consumption rate, inner membrane potential, cytochrome 
c release, swelling, reactive oxygen species, and individual 
respiratory chain complex (I–V) activities. Of the 31 KIs 
examined only three including sorafenib, regorafenib and 
pazopanib, all of which are hepatotoxic, caused significant 
mitochondrial toxicity at concentrations equal to the Cmax, 
indicating that mitochondrial toxicity likely contributes to 
the pathogenesis of hepatotoxicity associated with these 
KIs. At concentrations equal to 100-fold Cmax, 18 KIs were 
found to be toxic to mitochondria, and among six KIs with 
BBW-H, mitochondrial injury was induced by regorafenib, 
lapatinib, idelalisib, and pazopanib, but not ponatinib, or 
sunitinib. Mitochondrial liability at 100-fold Cmax had a 
positive predictive power (PPV) of 72% and negative pre-
dictive power (NPV) of 33% in predicting human KI hepa-
totoxicity as defined by product labeling, with the sensitiv-
ity and specificity being 62% and 44%, respectively. Similar 
predictive power was obtained using the criterion of Cmax 
≥1.1 µM or daily dose ≥100 mg. Mitochondrial liability 
at 1–2.5-fold Cmax showed a 100% PPV and specificity, 
though the NPV and sensitivity were 32% and 14%, respec-
tively. These data provide novel mechanistic insights into 
KI hepatotoxicity and indicate that mitochondrial toxicity at 
therapeutic levels can help identify hepatotoxic KIs.
Keywords Hepatotoxicity · Kinase inhibitor · Drug 
induced liver injury · Mitochondrion · Submitochondrial 
particles
Introduction
Drug-induced liver injury (DILI) is a major safety concern 
for patients, clinicians, pharmaceutical companies, and 
Abstract The FDA has approved 31 small-molecule kinase 
inhibitors (KIs) for human use as of November 2016, with 
six having black box warnings for hepatotoxicity (BBW-H) 
in product labeling. The precise mechanisms and risk fac-
tors for KI-induced hepatotoxicity are poorly understood. 
Here, the 31 KIs were tested in isolated rat liver mitochon-
dria, an in vitro system recently proposed to be a useful 
tool to predict drug-induced hepatotoxicity in humans. The 
KIs were incubated with mitochondria or submitochondrial 
particles at concentrations ranging from therapeutic maxi-
mal blood concentrations (Cmax) levels to 100-fold Cmax 
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regulatory agencies. Nearly 50% of orally administered 
drugs on the market have been linked to DILI, though the 
causality is not always clear (Weng et al. 2015b). DILI is 
of particular importance for small-molecule kinase inhibi-
tors (KIs), a group of recently developed drugs used to treat 
various types of cancer and other diseases such as idiopathic 
pulmonary fibrosis. They may be recommended for long-
term usage or to be used until unacceptable toxicity such as 
DILI is observed. In the product labeling, almost 20% (6 out 
of 31) of FDA approved KIs have a black box warning, the 
strongest safety warnings issued by the FDA, due to DILI, 
and 71% (22 out of 31) have a “Warnings and Precautions” 
section for DILI. The mechanisms and risk factors for KI 
hepatotoxicity may include metabolic activation (Castel-
lino et al. 2012; Teo et al. 2015), direct mitochondrial dam-
age (Weng et al. 2015a), oxidative stress (Xue et al. 2012), 
inhibition of hepatic transporters (Feng et al. 2009), and 
genetic variations in drug metabolism enzymes (Sugiyama 
et al. 2015; Takimoto et al. 2013). However, previous stud-
ies only investigated a small number (less than 10 in total) 
of KIs, and the results from different groups cannot be com-
pared directly, as different models and platforms were used. 
A comprehensive study involving all FDA approved KIs is 
needed to help better understand KI hepatotoxicity regard-
ing its mechanism and prediction for DILI.
Mitochondrial damage has long been recognized as 
an important mechanism for DILI (Meyers et al. 1988). 
Recent studies have gone a step further and provided evi-
dence that mitochondrial liability was predictive of a chem-
ical’s potential to induce DILI in humans (Aleo et al. 2014; 
Porceddu et al. 2012). However, few KIs have been exam-
ined regarding mitochondrial toxicity. In the present study, 
all 31 FDA approved KIs were tested in isolated rat liver 
mitochondria at concentrations normalized to blood levels 
at or above therapeutic doses in humans. Mitochondrial 
functions that were measured in the current study included: 
oxygen consumption rate, inner membrane potential 
(MMP), cytochrome c release which reflects outer mem-
brane integrity, swelling, reactive oxygen species (ROS), 
and the five individual respiratory chain complex (RCC 
I–V) activities. The results suggest that direct mitochon-
drial toxicity may contribute to the mechanism of hepato-
toxicity induced by some KIs, but the predictive power of 




KIs were obtained from three vendors including Med-
koo Biosciences (Chapel Hill, NC), Selleck Chemicals 
(Houston, TX), and LC laboratories (Woburn, MA). Rho-
damine 123 was from Cayman Chemical (Ann Arbor, MI). 
Cytochrome c profiling ELISA kit was from purchased 
Abcam Inc (Cambridge, MA). The ROS probe 5-(and-6)-
chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, 
acetyl ester (CM-H2DCFDA) was purchased from Thermo 
Fisher Scientific Inc (Grand Island, NY). Dimethyl sul-
foxide (DMSO), sodium dodecyl sulfate (SDS), and other 
chemicals were obtained from Sigma-Aldrich (St Louis, 
MO).
Characterization of commercial KIs by HPLC‑Mass 
spectrometry
KI stock solutions were prepared in DMSO and further 
diluted to 1 μg/ml as working standards with acetonitrile 
containing 0.1% formic acid. The solutions were stored 
at −20 °C until analysis. Ten μl of each KI solution was 
injected into a Waters e2695 Alliance HPLC System cou-
pled with both a Waters 2998 Photodiode Array (PDA) 
Detector and an ACQUITY QDa Mass Detector. Each 
analyte was eluted on a Waters Atlantis T3 C18 column 
(4.6 × 150 mm, 5 μm) at 40 °C using an isocratic mobile 
phase composed of 20% 10 mM ammonium formate and 
80% acetonitrile both containing 0.1% formic acid at a 
flow rate of 0.5 ml/min. The eluate was monitored for up 
to 10 min by the PDA and by mass spectrometry with the 
electrospray ion source operating in the positive ion mode 
(ESI+) using MS scans of 100–1000 Da.
Animal care
Sprague–Dawley rats (220–350 g) were obtained from the 
U.S. Food and Drug Administration National Center for 
Toxicological Research (NCTR) breeding colony. Animal 
care and experimental procedures were approved by the 
NCTR Institutional Animal Care and Use Committee in 
accordance with the National Institutes of Health (NIH) 
“Guide for the Care and Use of Laboratory Animals” 
(http://www.ncbi.nlm.nih.gov/books/NBK54050). Prelimi-
nary experiments showed that mitochondria from male and 
female rats responded similarly to KI treatment. Therefore, 
only male rats were used in subsequent studies.
Isolation of rat liver mitochondria
Rat liver mitochondria were prepared as described previ-
ously (Weng et al. 2015a). Rats were anesthetized by an 
intraperitoneal injection of Nembutal and the liver per-
fused with PBS to remove the blood. The liver was then cut 
into small pieces and homogenized using a Dounce type 
homogenizer in the ice-cold isolation buffer (IB) contain-
ing 200 mM sucrose, 10 mM Tris-MOPS, 1 mM EGTA 
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(pH 7.4). The sample was then centrifuged at 600g for 
10 min. The supernatant was further centrifuged at 7500g 
for 10 min, and the pellets was washed once with the IB 
and centrifuged again at 7500g for 10 min to collect mito-
chondria. The protein concentration was measured using 
the Bradford method (Kruger 1994). Before drug treat-
ment, the protein concentration was adjusted to 1 mg/ml 
using appropriate buffer. The purity of mitochondria was 
ascertained by detecting four mitochondrion-specific pro-
teins and the cytosolic protein glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) using Western blot (Gusdon 
et al. 2015). Briefly, mitochondrial and cytosolic frac-
tions from four different preparations using four rats were 
diluted using the Laemmli protein loading buffer and sub-
ject to SDS-PAGE with 4–20% gradient gels. The proteins 
were blotted to PVDF membranes and detected using anti-
bodies against GAPDH, ATP5A, UQCRC2, SDHB, and 
NDUFB8.
Drug treatment
The KI stock solutions were prepared in DMSO and ali-
quoted in 0.5 ml tubes before storing at −20 °C. The ali-
quoted stock solutions were kept for less than one month 
and each tube was used only once. The KIs were added to 
the mitochondria at 1:1000 dilutions. The final concentra-
tions for the majority of KIs were 100, 50, 30, 20, 10, 5, 
2.5, and 1-fold of Cmax as reported in the product labeling 
and drug approval packages at the official FDA website 
(https://www.accessdata.fda.gov/scripts/cder/drugsatfda). 
The Cmax data were from clinical trials which used FDA 
recommend dosages, route of administration, and duration. 
Several KIs were tested at lower concentrations because 
of the low solubility in DMSO or the tendency to precipi-
tate when added to test buffers or the interference with the 
assays. The final concentration of DMSO for drug treat-
ment was always 0.1%, and control treatments were 0.1% 
DMSO.
Mitochondrial oxygen consumption
A published procedure was followed to measure mitochon-
drial oxygen consumption (Weng et al. 2015a). Briefly, 
mitochondria were incubated with the KIs for 5 min, and 
then split evenly and loaded to the sample tubes of two 
Oxytherm systems (Hansatech Instruments Ltd), with one 
system used for measuring glutamate/malate driven respi-
ration and the other succinate-driven respiration, both of 
which were defined as state 4 respiration. After 3 min, ADP 
was added to measure the maximal oxygen consumption 
rate, which was defined as state 3 respiration. The buffer 
used for these experiments contained 125 mM KCl, 10 mM 
Tris-MOPS, 1 mM KH2PO4, 10 µM EGTA-Tris, pH7.4, 
and was referred to as respiration buffer (RB). The oxygen 
consumption rate of DMSO-treated samples (controls) was 
set as 1.
Measurement of MMP
MMP was measured using Rhodamine 123 as described in 
a previous report (Buron et al. 2010). Briefly, mitochon-
dria were suspended in RB supplemented with 5 mM suc-
cinic acid, 2 µM rotenone and 10 µM Rhodamine 123, and 
then KIs were added. The fluorescence (excitation 485 nm, 
emission 535 nm) was recorded every 1 min for 30 min 
using a Synergy 2 Multi-Mode microplate reader form 
BioTek (Winooski, VT).
Mitochondrial ROS production
ROS was measured using the fluorescence probe CM-
H2DCFDA (Mattiasson 2004). Briefly, freshly isolated 
mitochondria were diluted to 1 mg/ml using IB buffer con-
taining 4 µM CM-H2DCFDA. After 30 min, the samples 
were centrifuged at 7500 g for 10 min and the resulting 
pellet re-suspended in a buffer containing 150 mM KCl, 
5 mM KH2PO4, 5 mM Tris, 10 µM CaCl2, 2 µM rotenone, 
and 5 mM succinate (pH 7.4). KIs were then added, and 
100 µM CaCl2 was used as a positive control. The fluores-
cence (excitation 490 nm, emission 530 nm) was measured 
every 1 min for 30 min by using a Synergy 2 Multi-Mode 
microplate reader form BioTek (Winooski, VT). The signal 
from DMSO-treated samples was set as 1.
Activities of RCC I–V
The activities of RCC I–V were determined using previ-
ously published procedures (Kirby et al. 2007; Weng et al. 
2014). Submitochondrial particles were prepared by sub-
jecting the intact mitochondria to three successive freeze–
thaw cycles (Kirby et al. 2007). KIs were incubated with 
submitochondrial particles (1 mg/ml) for 15 min and then 
RCC I–V activities measured. The final KI concentrations 
ranged from 1–100 fold Cmax. The activities of DMSO-
treated samples (controls) were set as 1. RCC I activity 
was measured using a buffer containing 25 mM potassium 
phosphate, 5 mM MgCl2, pH7.2, 0.25% bovine serum albu-
min (BSA), 0.13 mM β-Nicotinamide adenine dinucleo-
tide, reduced dipotassium salt (NADH), 2 mM potassium 
cyanide (KCN), 2 µg/ml antimycin A and 65 µM ubiqui-
none 1, which was supplemented with or without 2 µg/
ml rotenone. The difference between the activity from 
rotenone-containing buffer and rotenone-absent buffer was 
considered as RCC I activity. RCC II activity was meas-
ured in a buffer containing 25 mM potassium phosphate, 
5 mM MgCl2, pH7.2, 20 mM sodium succinate, 50 µM 
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2,6-dichloroindophenol sodium salt hydrate, 2 mM KCN, 
2 µg/ml antimycin A, 2 µg/ml rotenone, and 65 µM ubiqui-
none 1. RCC III activity was determined with a buffer 
containing 25 mM potassium phosphate, pH 7.2, 1 mM 
n-dodecyl-β-D-maltoside, 1 mM KCN, 1 µg/ml rote-
none, 100 µM reduced-decylubiquinone, 15 µM oxidized 
cytochrome c, and 0.1% BSA. RCC IV activity was meas-
ured using a buffer containing 25 mM potassium phos-
phate, pH 7.2, 1 mM n-dodecyl-β-D-maltoside, 15 µM 
reduced cytochrome c. RCC V was measured with a buffer 
containing 40 mM Tris, 10 mM EGTA, pH 8.0, 0.2 mM 
NADH, 2.5 mM phospho(enol)pyruvic acid monopotas-
sium salt, 2.5 µg/ml antimycin A, 5 mM MgCl2, 5 U/ml lac-
tate dehydrogenase, 5 U/ml pyruvate kinase, and 2.5 mM 
ATP, which was supplemented with or without 2 µg/ml 
oligomycin A. The difference between the activity from 
oligomycin A-containing buffer and oligomycin A-absent 
buffer was considered as RCC V activity. For measuring 
RCC I/V and II activity, the changes in absorbance at 340 
and 600 nm, respectively, were determined every 1 min for 
6 min. For measuring RCC III and RCC IV, the changes in 
absorbance at 550 nm were measured every 10 s for 2 min.
Table 1  31 KIs tested in the present study
W&P warnings and precautions, BBW black box warnings, ALT alanine aminotransferase, NA not available. The 31 drugs are all FDA approved 
KIs for human use. Definition of DILI potential: 1, BBW and/or W&P indicated that the drug cased DILI; 0, no DILI information available in 
the labeling. The six KIs with a BBW for hepatotoxicity are highlighted in red
Drug name Approval date as a new 
molecular entity
Cmax (µM) Recommended daily dose 
(mg/day)
DILI potential (based  
on labeling)
labeling for DILI
Imatinib 10-May-01 2.00 600 1 W&P: fatal DILI
Gefitinib 5-May-03 0.27 250 1 W&P: fatal DILI
Erlotinib 18-Nov-04 3.44 150 1 W&P: fatal DILI
Sorafenib 20-Dec-05 4.30 400 1 W&P: fatal DILI
Sunitinib 26-Jan-06 0.12 44 1 BBW: fatal DILI
Dasatinib 28-Jun-06 0.18 120 0 NA
Lapatinib 13-Mar-07 4.18 1375 1 BBW: fatal DILI
Nilotinib 29-Oct-07 4.27 700 1 W&P: ALT↑/monitoring
Pazopanib 19-Oct-09 132.80 800 1 BBW: fatal DILI
Vandetanib 6-Apr-11 1.80 300 0 NA
Vemurafenib 17-Aug-11 0.13 960 1 W&P: hepatic impairment/
ALT monitoring
Crizotinib 26-Aug-11 0.91 500 1 W&P: fatal DILI
Ruxolitinib 16-Nov-11 1.20 25 0 NA
Axitinib 27-Jan-12 0.07 10 1 W&P: ALT↑/monitoring
Bosutinib 4-Sep-12 0.38 500 1 W&P: ALT↑/monitoring
Regorafenib 27-Sep-12 8.08 160 1 BBW: fatal DILI
Tofacitinib 6-Nov-12 0.09 10 1 W&P: ALT↑/monitoring
Cabozantinib 29-Nov-12 2.58 100 0 NA
Ponatinib 14-Dec-12 0.14 45 1 BBW: fatal DILI
Trametinib 29-May-13 0.04 2 0 NA
Dabrafenib 29-May-13 2.84 300 0 NA
Afatinib 12-Jul-13 0.04 40 1 W&P: ALT↑/monitoring
Ibrutinib 12-Feb-14 0.37 490 0 NA
Ceritinib 29-Apr-14 1.81 750 1 W&P: ALT↑/monitoring
Idelalisib 23-Jul-14 4.64 300 1 BBW: fatal DILI
Nintedanib 15-Oct-14 0.06 300 1 W&P: ALT↑/monitoring
Palbociclib 3-Feb-15 0.24 125 0 NA
Lenvatinib 13-Feb-15 0.68 24 1 W&P: fatal DILI
Cobimetinib 10-Nov-15 0.51 60 1 W&P: ALT↑/monitoring
Osimertinib 13-Nov-15 0.50 80 0 NA




A previously published procedure was followed in detail 
for measuring mitochondrial swelling (Weng et al. 2015a).
Cytochrome c release assay
Freshly isolated liver mitochondria (1 mg/ml protein) were 
re-suspended in RB supplemented with 5 mM succinic acid 
and 2 µM rotenone, and then KIs were added, with DMSO 
used as a vehicle control and alamethicin as a positive 
control whose signal was set as 100 (Buron et al. 2010). 
The samples were incubated for 30 min with gentle shak-
ing. After centrifugation 10,000g for 10 min, the superna-
tant and pellets were collected and kept at −80 °C. The 
cytochrome c level in the supernatant was determined using 
the cytochrome c profiling ELISA Kit from Abcam Inc. 
(Cambridge, MA) following the manufacturer’s manual. 
As the antibody only reacts with denatured cytochrome c, it 
is of critical importance to incubate the supernatant with a 
buffer containing 1% SDS prior to measurement.
Data analysis
The means and standard deviations were obtained from at 
least three batches of mitochondria isolated from three dif-
ferent Sprague–Dawley male rats. The difference among 
treatment groups were analyzed by one-way or two-way 
ANOVA followed by Dunnett’s test using the software 
GraphPad Prism 6 (San Diego, California). A p value less 
than 0.05 was considered statistically meaningful. The 
positive prediction value (PPV), negative prediction value 
(NPV), sensitivity, and specificity were calculated as previ-
ously described (Porceddu et al. 2012).
Results
Overview of tested KIs
All FDA approved small-molecule KIs were retrieved 




of November 2016, the FDA has approved 31 KIs for 
human use. The Cmax, recommended daily dose, date 
of approval, and DILI potential of these drugs are sum-
marized in Table 1. The recommended daily dose of 
these KIs ranged from 2 to 1375 mg, and the therapeutic 
Cmax ranged from 0.04 to 132.80 µM, a span of about 
three orders of magnitude, highlighting the importance of 
normalizing the test concentrations to Cmax for in vitro 
studies comparing KI toxicities. The chemical structure 
and molecular weight of KIs tested in this study were 
ascertained using mass spectrometry-based technology 
Table 2  Pharmacological targets and DILI potentials of FDA approved KIs
* indicates the KIs with a black box warning for hepatotoxicity
Targets DILI positive KIs DILI negative KIs % of DILI positive KIs (# 
of positive/negative KIs)
ALK Crizotinib; ceritinib; alectinib None 100% (3/0)
PDGFR Imatinib; sorafenib; sunitinib*; nilotinib; pazopanib*; 
axitinib; regorafenib*; ponatinib*; nintedanib; lenvatinib
Dasatinib 91% (10/1)
BCR-Abl Imatinib; nilotinib; bosutinib; regorafenib*; ponatinib* Dasatinib 83% (5/1)





Flt3 Sorafenib; sunitinib*; ponatinib*; nintedanib Cabozantinib 80% (4/1)
Kit Imatinib; sorafenib; sunitinib*;
Pazopanib*; regorafenib*; ponatinib *; lenvatinib
Dasatinib; cabozantinib 78% (7/2)
RET Sorafenib; sunitinib*; regorafenib*; ponatinib*; len-
vatinib; alectinib
Vandetanib; cabozantinib 75% (6/2)
B-Raf Sorafenib; vemurafenib; regorafenib* Dabrafenib 75% (3/1)
EGFR Gefitinib; erlotinib; lapatinib*; afatinib Vandetanib; osimertinib 67% (4/2)
EphR Regorafenib*; ponatinib* Dasatinib; vandetanib 50% (2/2)
Src Bosutinib; ponatinib* Dasatinib; vandetanib 50% (2/2)
Tie2 Regorafenib*; ponatinib* Vandetanib; cabozantinib 50% (2/2)
MEK Cobimetinib Trametinib 50% (1/1)
JAK Tofacitinib Ruxolitinib 50% (1/1)
Lck Pazopanib Dasatinib 50% (1/1)
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(Supplementary Fig. 1). No quality issues were identified 
with these commercial KIs.
The known pharmacological targets of these KIs were 
collected from http://www.brimr.org/PKI/PKIs.htm and 
drug labeling from https://dailymed.nlm.nih.gov/dailymed/
index.cfm (Supplementary Table 1). The pharmacological 
targets associated with at least two approved KIs were listed 
in Table 2. The targets were listed according to the percent-
age of DILI positive KIs among each group. An interesting 
observation is that all 3 ALK inhibitors and 91% (10 out of 
11) of PDGFR inhibitors are hepatotoxic. It is likely that KIs 
targeting these two pathways have exceptionally high risks 
of liver injury. As for several other targets, such as EphR, 
Sec and Tie2, only 50% of the corresponding KIs are hepa-
totoxic. This is in line with the observation that about 50% 
(478 out of 975) of oral drugs have been associated with 
DILI (Weng et al. 2015b), indicating that targeting these 
kinase pathways is unlikely to cause additional DILI risks. 
However, definitive conclusions cannot be drawn at this 
time, as the number of KIs in each group is relatively small.
Fig. 1  KI effects on mitochondrial oxygen consumption. Rat liver 
mitochondria were incubated with KIs at 100-fold Cmax or the maxi-
mal testable concentrations as indicated. The KIs in the X-axis were 
listed according to their approval date. The six KIs with a black box 
warning for hepatotoxicity were highlighted in a red box. The Y-axis 
represents the fold changes of oxygen consumption after KI treatment 
as compared to DMSO-treated samples. a, b Represent the oxygen 
consumption rate measured using glutamate/malate and succinate, 
respectively. Data are means and standard derivations from three sep-




KI effects on mitochondrial oxygen consumption
Before drug treatment, the purity of mitochondria from 
selective rats was examined using Western blot. As shown 
in Supplementary Fig. 2A, the cytosolic protein GAPDH 
was only detectable in cytosolic fractions but not mito-
chondrial preparations. In contrast, the four mitochondrion-
specific proteins including ATP5A, UQCRC2, SDHB and 
NDUFB8 were only detectable in mitochondrial prepara-
tions but not cytosolic fractions (Supplementary Fig. 2B). 
These results indicate that our mitochondria were devoid of 
cytosolic contamination.
Oxygen consumption is one of the most important func-
tions of mitochondria that can be affected by hepatotoxic 
drugs. Figure 1 shows the mitochondrial oxygen consump-
tion rate after KI treatment at the highest tested concentra-
tions, and the dose dependent effects of 11 KIs that showed 
significant effects in Fig. 1 are presented in Table 3. The 
remaining data are included in Supplementary Table 1. 
Three KIs, including sorafenib, pazopanib and regorafenib, 
significantly affected oxygen consumption starting at con-
centrations equal to Cmax, while two KIs, dabrafenib and 
cabozantinib, began to show detrimental effects staring 
from tenfold Cmax (Table 3). Ruxolitinib and three other 
KIs (imatinib, ceritinib and lenvatinib) disrupted oxygen 
consumption starting from 20- and 30-fold Cmax, respec-
tively. Idelalisib was non-effective until 50-fold Cmax, and 
crizotinib only affected oxygen consumption at 100-fold 
Cmax (Table 3). 
At the highest tested concentrations, four drugs, includ-
ing sorafenib, regorafenib, cabozantinib and dabrafenib 
caused significant increases of state 4 respiration (Fig. 1), 
indicating these drugs uncoupled oxidative phosphorylation 
(OXPHOS). Seven KIs decreased state 3 respiration driven 
by glutamate/malate (Fig. 1a), and four KIs suppressed 
state 3 respiration driven by succinate (Fig. 1b), indicating 
these drugs were likely inhibitors of OXPHOS. Of note, 
ceritinib caused almost 100% inhibition of mitochondrial 
oxygen consumption, albeit at 100-fold Cmax.
KI effects on activities of RCC I–V
The inhibitory effects of KIs on mitochondrial oxygen 
consumption might be due to the direct inhibition of RCC 
activities by KIs. To identify the specific RCCs inhibited by 
KIs, the activities of RCC I–V were measured using sub-
mitochondrial particles. KIs concentrations tested were the 
same as described for intact mitochondria. The results of 
all 31 KIs at the highest tested concentrations are shown in 
Fig. 2a–e, and the dose dependent responses for the 11 KIs 
that significantly inhibited RCCs were presented in Table 4. 
The “negative” results are included in Supplementary 
Table 3  Dose response of KI effects on mitochondrial oxygen con-
sumption
The signal from DMSO-treated samples was set as 1. * p < 0.05 as 
compared to DMSO-treated samples. The next lower concentrations 







State 4 State 3 State 4 State 3
Sorafenib
 10 5.00 ± 1.92* 0.93 ± 0.34 3.34 ± 0.45* 1.03 ± 0.19
 5 3.69 ± 0.12* 1.34 ± 0.04* 1.03 ± 0.08 0.40 ± 0.01*
 2.5 4.92 ± 0.09* 1.57 ± 0.06* 1.43 ± 0.06* 0.62 ± 0.05*
 1 2.55 ± 0.27* 1.15 ± 0.09 1.50 ± 0.21* 1.00 ± 0.10
Regorafenib
 10 3.84 ± 0.34* 1.36 ± 0.03* 1.78 ± 0.19* 0.82 ± 0.19
 5 3.82 ± 0.72* 1.33 ± 0.04* 1.69 ± 0.09* 0.83 ± 0.03
 2.5 5.51 ± 0.35* 2.51 ± 0.04* 3.59 ± 0.14* 0.84 ± 0.04
 1 7.45 ± 0.17* 2.33 ± 0.06* 2.95 ± 0.08* 1.05 ± 0.07
Pazopanib
 1 1.05 ± 0.15 0.43 ± 0.06* 1.01 ± 0.11 0.86 ± 0.09
Dabrafenib
 100 2.49 ± 0.32* 0.41 ± 0.05* 1.03 ± 0.09 0.28 ± 0.01*
 50 2.42 ± 0.21* 0.56 ± 0.05* 1.69 ± 0.30* 0.44 ± 0.10*
 30 2.22 ± 0.24* 0.71 ± 0.03* 1.52 ± 0.12* 0.59 ± 0.07*
 20 1.59 ± 0.05* 0.90 ± 0.05 1.31 ± 0.02* 0.65 ± 0.01*
 10 1.35 ± 0.19* 0.94 ± 0.04 1.38 ± 0.13* 0.97 ± 0.07
Cabozantinib
 30 1.55 ± 0.06* 0.94 ± 0.05 1.35 ± 0.18* 0.95 ± 0.05
 20 1.30 ± 0.15* 0.92 ± 0.05 1.24 ± 0.05* 0.94 ± 0.06
 10 1.46 ± 0.08* 1.01 ± 0.03 1.23 ± 0.11* 1.03 ± 0.01
Ruxolitinib
 100 0.71 ± 0.08* 0.28 ± 0.06* 1.17 ± 0.12 0.99 ± 0.03
 50 0.97 ± 0.20 0.49 ± 0.06* 1.07 ± 0.07 0.87 ± 0.08
 30 1.00 ± 0.09 0.54 ± 0.02* 1.08 ± 0.09 1.05 ± 0.11
 20 0.81 ± 0.05 0.62 ± 0.05* 1.00 ± 0.14 0.90 ± 0.13
Ceritinib
 100 0.50 ± 0.06* 0.08 ± 0.02* 0.17 ± 0.10* 0.03 ± 0.02*
 50 1.21 ± 0.12* 0.55 ± 0.03* 0.77 ± 0.07* 0.45 ± 0.08*
 30 1.12 ± 0.13 0.88 ± 0.05 0.70 ± 0.12* 0.41 ± 0.18*
Imatinib
 100 0.90 ± 0.12 0.70 ± 0.11* 1.04 ± 0.06 0.93 ± 0.07
 50 0.90 ± 0.06 0.67 ± 0.03* 0.99 ± 0.06 0.90 ± 0.01
 30 0.93 ± 0.04 0.71 ± 0.02* 0.98 ± 0.02 0.94 ± 0.04
Lenvatinib
 100 1.06 ± 0.06 0.74 ± 0.04* 1.07 ± 0.03 0.99 ± 0.03
 50 0.93 ± 0.01 0.70 ± 0.02* 0.96 ± 0.03 0.90 ± 0.01
 30 0.95 ± 0.06 0.76 ± 0.05* 0.94 ± 0.01 0.86 ± 0.04
Idelalisib
 100 1.13 ± 0.05 0.66 ± 0.03* 1.05 ± 0.01 0.65 ± 0.03*
 50 1.00 ± 0.08 0.76 ± 0.04* 0.97 ± 0.04 0.83 ± 0.06
Crizotinib
 100 0.97 ± 0.14 0.86 ± 0.15 1.09 ± 0.12 0.80 ± 0.08*
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Fig. 2  KI effects on activities of RCC I–V. Submitochondrial parti-
cles were incubated with KIs at 100-fold Cmax or the highest test-
able concentrations as. After 15 min, the activities of RCC I–V were 
measured. a, b, c, d, e Represents the activity of RCC I, II, III, IV, 
and V, respectively. The drugs in the X-axis were listed according to 
their approval date. The six KIs with a black box warning for hepato-
toxicity were highlighted in a red box. The Y-axis represents the per-
centage of RCC activity after KI treatment as compared to DMSO-
treated samples which were set as 100. Data are means and standard 
derivations from three independent experiments. *p < 0.05 as com-
pared to DMSO-treated samples (color figure online)
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Table 1. Pazopanib was the only KI that inhibited RCCs at 
concentrations equal to Cmax, and sorafenib was the next 
toxic KIs as it started to inhibit RCCs at fivefold Cmax. 
Regorafenib and erlotinib began to suppress RCCs at 10- 
fold Cmax, and the other KIs showed detrimental effect 
only at concentrations equal or larger than 20-fold Cmax. At 
the highest tested concentrations, the number of KIs inhibit-
ing RCC I, II, III, IV, and V was 8, 3, 1, 1, and 3, respec-
tively. It was evident that RCC I was the major target for KI 
inhibition. The drug ceritinib was the only KI that caused 
inhibition of all five RCCs, and cabozantinib inhibited both 
RCC I and RCC II. For other KIs with RCC inhibition, the 
effects appeared protein complex-specific. For example, 
imatinib, regorafenib, and sorafenib only inhibited RCC I, 
RCC II and RCC V, respectively, but not other RCCs.
KI effects on MMP
Uncoupling of mitochondrial respiration can disrupt 
MMP. Among 31 KIs tested, only five drugs including 
regorafenib, ceritinib, dabrafenib, sorafenib and cabozan-
tinib caused a decrease in MMP at the highest concentra-
tions tested (Fig. 3a), and the remaining drugs showed no 
effects at any of the concentrations tested (Fig. 3b; Sup-
plementary Table 1). Among the five effective drugs, ceri-
tinib showed the strongest potential. Dose–response studies 
showed that sorafenib and regorafenib started to decrease 
MMP at onefold Cmax, and cabozantinib and dabrafenib 
at tenfold and 20-fold Cmax, respectively, while ceritinib 
showed no effects at concentrations lower than 100-fold 
Cmax (Fig. 3c).
Fig. 2  continued
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KI effects on mitochondrial swelling
Altered permeability of the mitochondrial inner mem-
brane can lead to swelling. Figure 4a shows that seven KIs 
including regorafenib, sorafenib, dabrafenib, cabozantinib, 
ceritinib, crizotinib and vandetanib caused significant mito-
chondrial swelling at the highest concentrations tested. Other 
drugs tested showed no effects on mitochondrial swelling 
at any of the concentrations tested (Fig. 4b; Supplementary 
Table 1). The dose response of five effective KIs is presented 
in Fig. 4c. Only one drug regorafenib caused mitochondrial 
swelling at onefold Cmax, and sorafenib caused swelling at 
2.5-fold Cmax (Supplementary Table 1). Of note, though 
regorafenib at onefold Cmax caused almost maximal swell-
ing, it was not possible for us to test it reliably at the next 
higher concentrations (2.5-fold Cmax), because absorbance 
at 535 nm of the drug itself was observed. This was also the 
case for sorafenib. Therefore, the dose response curves were 
not presented in the main text. Figure 4c shows that dab-
rafenib and cabozantinib started to cause swelling at tenfold 
and 20-fold Cmax, respectively. The remaining three drugs 
including ceritinib, crizotinib, and vandetanib only caused 
swelling at 100-fold Cmax.
KI effects on cytochrome c release
Changes in the permeability of mitochondrial outer mem-
brane can lead to cytochrome c release. Figure 5a shows 
that 11 KIs induced cytochrome c release at the high-
est concentrations tested, and the remaining 20 KIs were 
ineffective. The dose response of seven KIs was shown in 
Fig. 5b–d. Only regorafenib started to trigger cytochrome c 
Table 4  Dose response of KI effects on activities of RCC I–V
The signal from DMSO-treated samples was set as 100. * p < 0.05 as compared to DMSO-treated samples. The next lower concentrations 
showed no effects. KIs not listed also showed no effects
Drugs (fold of Cmax) RCC activity (100% of control)
I II III IV V
Pazopanib
 1 83.77 ± 2.98* 96.12 ± 2.96 96.90 ± 11.69 102.68 ± 0.57 92.22 ± 10.47
Sorafenib
 10 85.45 ± 11.93 103.68 ± 7.88 94.31 ± 7.47 107.65 ± 10.77 65.55 ± 6.34*
 5 87.23 ± 10.61 101.40 ± 6.29 97.60 ± 5.50 101.55 ± 3.61 78.30 ± 4.68*
Erlotinib
 10 90.62 ± 2.87 93.97 ± 12.92 103.11 ± 12.25 98.77 ± 4.53 83.52 ± 2.96*
Regorafenib
 10 99.37 ± 3.35 83.50 ± 2.91* 90.31 ± 13.61 95.37 ± 6.45 90.36 ± 13.39
Crizotinib
 100 60.51 ± 8.90* 84.10 ± 6.53 103.28 ± 2.85 96.60 ± 8.40 100.80 ± 13.09
 50 71.46 ± 4.28* 90.31 ± 4.38 98.02 ± 7.16 103.77 ± 5.67 91.95 ± 5.63
 30 76.48 ± 2.18* 95.03 ± 1.23 106.26 ± 5.79 96.65 ± 4.14 98.65 ± 2.98
 20 86.52 ± 2.70* 100.85 ± 3.65 99.67 ± 8.65 94.03 ± 9.67 95.77 ± 7.64
Alectinib
 20 89.39 ± 2.98* 98.44 ± 10.74 116.05 ± 4.72 101.46 ± 1.66 106.30 ± 11.74
Cabozantinib
 30 80.97 ± 2.99* 79.26 ± 6.01* 90.73 ± 14.60 113.10 ± 9.48 91.99 ± 8.51
Ceritinib
 100 63.74 ± 13.12* 69.91 ± 10.00* 68.48 ± 6.59* 71.46 ± 7.39* 34.25 ± 2.09*
 50 94.04 ± 3.32 89.14 ± 6.26 103.80 ± 5.19 82.33 ± 3.68* 71.23 ± 9.65*
Vandetanib
 100 65.88 ± 7.15* 92.39 ± 2.47 91.23 ± 6.54 103.06 ± 12.96 85.15 ± 8.36
 50 87.71 ± 0.58* 90.03 ± 5.23 99.20 ± 5.61 100.56 ± 2.67 95.65 ± 4.66
Imatinib
 100 85.30 ± 5.13* 102.36 ± 5.33 104.96 ± 10.18 107.65 ± 4.65 79.34 ± 10.06
Bosutinib
 100 88.03 ± 3.01* 91.74 ± 11.35 101.81 ± 4.43 101.25 ± 2.26 91.53 ± 6.49
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release at onefold Cmax (Fig. 5b), and two drugs, sorafenib 
and dabrafenib, caused cytochrome c release starting at 
fivefold Cmax (Fig. 5c, d). Lapatinib caused cytochrome 
release only at tenfold Cmax, though higher concentra-
tions cannot be tested due to its limited solubility (Sup-
plementary Table 1). Four KIs including ceritinib, ruxoli-
tinib, crizotinib and imatinib began to cause cytochrome 
c at 50-fold Cmax (Fig. 5d), and three KIs including van-
detanib, tofacitinib, osimertinib only showed significant 
effects at 100-fold Cmax. Among all 31 KIs tested, ceri-
tinib caused the most significant cytochrome c release, that 
is, 33% of total cytochrome c was leaked after treatment, 
though this occurred at 100-fold Cmax (Fig. 5d).
KI effects on ROS production in mitochondria
ROS is produced at low levels during normal mitochondrial 
respiration. Drug-induced inhibition of oxygen consump-
tion can lead to ROS overproduction. As shown in Fig. 6a, 
calcium chloride induced a threefold increase in ROS pro-
duction. However, none of the KIs caused ROS over pro-
duction in mitochondria at 1 to 10 fold Cmax (Supplemen-
tary Table 1). At the highest tested concentrations, four KIs 
including crizotinib, dabrafenib, ceritinib, and osimertinib 
caused significantly ROS production (Fig. 6a). The dose 
response of these four KIs is shown in Fig. 6b. While cri-
zotinib and osimertinib trigger ROS overproduction begin-
ning from 20-fold and 30-fold Cmax, respectively, dab-
rafenib and ceritinib only started to show significant effects 
from 50-fold Cmax. The magnitude of ROS production 
induced by osimertinib at 100-fold Cmax was even slightly 
higher than those caused by calcium chloride.
Prediction of KI hepatotoxicity using mitotoxicity 
as compared to daily dose and Cmax
Table 5 shows the results of using KI mitotoxicity to pre-
dict hepatotoxicity. For this purpose, the drugs that can-
not be tested at higher concentrations due to solubility 
issues will be either considered as mitotoxicity positive 
if they showed positive mitotoxicity at lower concentra-
tions or excluded at untestable concentrations when low 
concentrations showed no mitotoxicity. At 100-fold Cmax 
with intact mitochondria, the PPV was 67% and NPV was 
only 31%, and the corresponding sensitivity and specific-
ity was 53 and 44%, respectively. At 100-fold Cmax with 
both intact mitochondria and submitochondrial particles, 
though the specificity was not affect, other parameters 
were all increased, indicating that inclusion of submito-
chondrial particles enhanced the predictive power. At one-
fold Cmax with intact mitochondria, the PPV and speci-
ficity was all 100%, but NPV and sensitivity was only 32 
and 13%, respectively. The results at other concentrations 
were presented in Supplementary Table 2. The overall 
results were that though the PPV was decent, the NPV 
was always no greater than 50%. Interestingly, using a 
cutoff of Cmax ≥ 1.1 µM (Shah et al. 2015) or daily dose 
≥100 mg (Weng et al. 2015b), similar predictive results 
were obtained as using mitotoxicity data (Supplementary 
Table 2).
Discussion
Though several KIs have been investigated in previous 
reports regarding mitochondrial toxicity, a comprehensive 
study involving all FDA approved KIs is not yet available. 
In addition, KI effects from previous reports cannot be com-
pared directly, as different platforms were used. This study 
not only significantly expanded the number of KIs tested for 
mitochondrial toxicity, but also provided additional data on 
mitochondrial liabilities such as ROS production and RCC 
activities that were not examined in previous studies.
Some endpoints measured in this study can be related. 
For example, an uncoupler can disrupt inner membrane 
potential, and RCC inhibition may cause ROS overproduc-
tion, and cytochrome c release can affect oxygen consump-
tion. However, the relation is not always causative. For 
example, the increase in ROS production caused by mild 
RCC inhibition can be antagonized by endogenous antioxi-
dant. Another example is that RCC inhibition can decrease 
oxygen consumption and uncoupling can enhance oxygen 
consumption, and therefore if a KI is both a RCC inhibi-
tor and an uncoupler, such as sorafenib, the net effects on 
oxygen consumption can be complicated. Further studies 
are needed to clarify the relations among mitochondrial 
changes caused by KIs.
Of the 31 KIs examined only three including sorafenib, 
regorafenib and pazopanib, all of which are DILI positive, 
caused significant mitochondrial toxicity at concentrations 
equal to the Cmax. At similar concentrations, sorafenib has 
been shown to be an uncoupler and inhibitor of OXPHOS 
in isolated rat heart mitochondria (Will et al. 2008) and 
regorafenib is reported to be a pure uncoupler without inhi-
bition of OXPHOS in isolated rat liver mitochondria (Weng 
et al. 2015a), while no data are available for pazopanib. 
This study showed that sorafenib affected rat liver mito-
chondria in a similar manner as reported in rat heart mito-
chondria (Will et al. 2008). Sorafenib was also reported to 
be a strong mitochondrial toxicant in neuroblastoma cells 
(Bull et al. 2012). Collectively, these data suggest that 
sorafenib-induced effects on mitochondria are not tissue 
specific, and that mitochondrial toxicity may contribute to 
various types of organ toxicity associated with sorafenib. 
This study also identified an additional mitochondrial 





(Weng et al. 2015a), that is, regorafenib caused cytochrome 
c release at a concentration equal to Cmax. Of note is that 
the chemical structures of sorafenib and regorafenib are 
very similar (Supplementary Fig. 1). This study found that 
both drugs were uncouplers and both caused cytochrome c 
release, a decreased in MMP, and mitochondrial swelling, 
while neither of them affected ROS production. It appears 
likely that sorafenib and regorafenib share chemical prop-
erties that are associated with mitochondrial injury leading 
to organ toxicity.
The drug pazopanib, which carries a BBW for DILI on 
its labeling, has the highest Cmax (133 µM) among all KIs 
examined and it is not possible to test its effects at more 
than onefold Cmax concentrations due to the solubility 
issue. At onefold Cmax, pazopanib inhibited state 3 mito-
chondrial respiration driven by glutamate/malate by over 
50%, but showed no effects on succinate-driven respiration, 
indicating that pazopanib may specifically inhibit RCC I. 
Indeed, with submitochondrial particles, pazopanib was 
confirmed to be an inhibitor of RCC I but not other RCCs. 
These data suggest that selective inhibition of RCC I may 
contribute to the pathogenesis of pazopanib hepatotoxicity.
The drugs ponatinib and sunitinib have BBWs for DILI 
in the labeling. However, both drugs showed no effects on 
intact mitochondria or submitochondrial particles even at 
the highest concentrations tested, indicating that mitochon-
drial liability at 100-Cmax would not predict DILI positive 
KI with high confidence. Alternative mechanisms, such 
as reactive metabolites, may account for DILI associated 
with these two drugs. Our findings on sunitinib with intact 
mitochondria are consistent with previous reports carried 
out either in rat heart mitochondria (Will et al. 2008) or 
mouse liver mitochondria (Porceddu et al. 2012). How-
ever, in the latter mouse study, sunitinib was considered as 
mitochondrial toxicity positive, as the authors determined 
that the Cmax of sunitinib was 70.8 µM (Porceddu et al. 
2012), which is sharp contrast with ours (0.12 µM) and oth-
ers’ (0.25 µM) (Will et al. 2008). If the true Cmax of suni-
tinib was 70.8 µM, it would not be feasible for us to have it 
tested at 100-fold Cmax due to the solubility issue.
The DILI negative drug vandetanib inhibited RCC I 
starting at 50-fold Cmax, but had no effects on mitochon-
drial oxygen consumption even at 100-fold Cmax. The 
likely reason for this discrepancy is that RCC activities 
need to be measured using submitochondrial particles, 
while oxygen consumption is determined using intact 
mitochondria. Differential effects of chemicals on whole 
mitochondria and submitochondrial particles have been 
reported previously, and one likely reason, among many 
others, was that the compound may not easily cross the 
inner membrane and therefore RCC proteins were pro-
tected from the drug’s effects with intact mitochondria 
(Weng et al. 2014). Further investigations are needed to 
confirm if this is true for vandetanib and other KIs show-
ing similar effects. On the other hand, another DILI 
negative drug dabrafenib caused significant inhibition of 
state 3 respiration in intact mitochondria but showed no 
effects on RCC activities in submitochondrial particles. 
The likely reason for this discrepancy is that dabrafenib 
also caused cytochrome c release leading to suppressed 
oxygen consumption. It should be pointed out that these 
two DILI negative drugs indeed caused various types of 
mitochondrial injury at 100-fold Cmax, implying that 
mitochondrial liability at 100-Cmax is not a good predic-
tor of DILI negative KIs. Further supporting this premise, 
the DILI negative drugs dabrafenib, cabozantinib, ruxoli-
tinib, osimertinib, and ibrutinib also showed significant 
toxicity to intact mitochondria at concentrations starting 
from 5-fold, 10-fold, 20-fold, 30-fold, and 50-fold Cmax, 
respectively. Interestingly, one of the veterinary KIs 
oclacitinib has not been associated with DILI in animals. 
However, at 50-fold Cmax, oclacitinib caused significant 
cytochrome c release from intact mitochondria (data not 
shown). Taken together, these data indicate that mitochon-
drial toxicity was too sensitive in predicting DILI nega-
tive KIs. However, the possibility that the DILI potential 
of these KIs has not been fully recognized from clinical 
use cannot be ruled out.
The predictive power of the mitochondrial model for 
KI hepatotoxicity presented here is in contrast to a previ-
ous report showing that human DILI in general can be pre-
dicted with high confidence using in vitro mitochondrial 
endpoints measured at 100-fold Cmax (Porceddu et al. 
2012). The likely reason for this discrepancy is that KI 
hepatotoxicity may differ from DILI caused by other thera-
peutic groups of drugs. To our knowledge, though several 
in vitro systems have been proposed to be effective in pre-
dicting a compound’s DILI potential, no previous studies 
have included all FDA approved KIs for this purpose. Our 
findings highlight the challenge posed by KIs for predicting 
DILI using mitochondrial assays and warrant further inves-
tigations using alternative in vitro systems.
An interesting observation is that mitochondrial toxic-
ity at onefold and 2.5-fold Cmax showed 100% PPV and 
100% specificity in predicting KI hepatotoxicity, though 
the NPV and sensitivity were 32 and 14%, respectively. 
Fig. 3  KI effects on mitochondrial inner membrane potential 
(MMP). Rat liver mitochondria were supplemented with 10 µM Rho-
damine 123 and incubated with KIs at 100-fold Cmax or the high-
est testable concentrations as indicated. The fluorescence (excitation 
485 nm, emission 535 nm) was recorded every 1 min for 30 min and 
presented in the Y-axis (a, b). c Shows the dose response of five KIs. 
In a, c, data are means and standard derivations from three separate 
experiments. *p < 0.05 as compared to DMSO-treated samples at the 







This indicates that if a drug causes mitotoxicity in any of 
the endpoints assessed at concentrations equal to Cmax, 
it will very likely be DILI positive; however, a drug being 
non-mitotoxic at Cmax does not mean that it will be DILI 
negative, as alternative or indirect mechanisms may be 
involved. It appears that mitotoxicity at 1–2.5-fold Cmax 
can be used to help identify hepatotoxic KIs as an early 
safety screen during drug discovery.
Many drugs impair mitochondrial functions contribut-
ing to DILI pathogenesis, although only a few have been 
directly tested in vivo or in humans (McGill et al. 2012). 
Drugs affecting mitochondrial functions in vitro at clini-
cally relevant concentrations are expected to have a high 
likelihood of doing so under in vivo conditions. This 
study identified several KIs causing significant mitochon-
drial injury at concentrations equal to Cmax or only at 
Fig. 4  KI effects on mitochondrial swelling. Rat liver mitochondria 
were supplemented with 25 µM calcium chloride and incubated with 
KIs at 100-fold Cmax or the highest testable concentrations as indi-
cated. The six KIs with a black box warning for hepatotoxicity were 
highlighted in a red box. Mitochondrial swelling was determined by 
monitoring the decrease in absorbance at 535 nm every 2 min for 
30 min. c Shows the dose response of five KIs. a, c Data are means 
and standard derivations of three separate experiments. *p < 0.05 as 
compared to DMSO-treated samples at the end of experiments. b 
Data are means of two independent experiments (color figure online)
◂
Fig. 5  KI effects on cytochrome c release. Rat liver mitochondria 
were incubated with KIs at 100-fold Cmax or the highest testable 
concentrations as indicated. Alamethicin was used to induce complete 
cytochrome c release, and its signal was set as 100. After 30 min, the 
mitochondria were pelleted and cytochrome c level in the supernatant 
was determined using an ELISA Kit. The drugs in the X-axis were 
listed according to their approval date. The six KIs with a black box 
warning for hepatotoxicity were highlighted in a red box (a). b–d Are 
the dose response of seven KIs. Data are means and standard deriva-
tions from three independent experiments. *p < 0.05 as compared to 
DMSO-treated samples (color figure online)
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several fold of Cmax. These drugs can serve as good can-
didates for future exploratory in vivo studies. Mitochon-
drion-enriched molecules, such as mitochondrial DNA 
and cytochrome c, can be released into the blood when 
liver injury is induced by drugs causing mitochondrial 
damage, and circulating mitochondrial molecules have 
Fig. 6  KI effects on ROS production in mitochondria. Rat liver mito-
chondria were loaded with 4 µM CM-H2DCFDA and then treated 
with KIs at 100-fold Cmax or the highest testable concentrations as 
indicated. Calcium chloride was used as a positive control. The fluo-
rescence (excitation 490 nm, emission 530 nm) was measured every 
1 min for 30 min. The signal from DMSO-treated samples was set 
as 1. The drugs in the X-axis were listed according to their approval 
date. The six KIs with a black box warning for hepatotoxicity were 
highlighted in a red box (a). b Shows the dose response of four KIs. 
Data are means and standard derivations from three independent 
experiments. *p < 0.05 as compared to DMSO-treated samples (color 
figure online)
Table 5  Prediction of KI hepatotoxicity by using mitotoxicity at different concentrations
PPV positive predictive value, NPV negative predictive value, DILI drug-induced liver injury. A drug is considered as mitotoxicity positive (+) 
if it causes at least one type of mitochondrial injury. Intact-mito: data from whole mitochondria; Sub-mito: data from submitochondrial particles
Fold of Cmax Test system Mitotoxicity DILI+ DILI− PPV NPV Sensitivity Specificity
100 Intact-mito (excluded 3 drugs) + 10 5 67% 31% 53% 44%
− 9 4
Intact and Sub-mito (excluded 1 drug) + 13 5 72% 33% 62% 44%
− 8 4
1 Intact-mito + 3 0 100% 32% 14% 100%
− 19 9




been shown to be novel biomarkers for DILI induced 
by mitotoxic drugs (Miller et al. 2008; Shi et al. 2015). 
It is worthwhile to examine if KI hepatotoxicity can be 
monitored using circulating mitochondrial biomarkers. 
The KIs that showed the strongest mitochondrial toxici-
ties, such as sorafenib, regorafenib, and pazopanib, are 
particularly suitable for testing this hypothesis in future 
investigations.
It should be pointed out that the DILI potential of some 
drugs was not fully recognized until being marketed for 
many years (Rivkees 2010). As most KIs were approved 
very recently, the DILI potential of these drugs may not be 
thoroughly understood until more time has passed. There-
fore, the predictive results presented here may change over 
time as more patients take these drugs. Nevertheless, our 
findings demonstrate that mitochondrial toxicity has limited 
predictive power for human DILI observed in clinical tri-
als and post-marketing, studies that laid the foundation for 
drug approval and labeling. Alternative in vitro approaches, 
such as primary hepatocytes or human-induced pluripotent 
stem cell-derived hepatocytes, may partially overcome key 
disadvantages of isolated mitochondria, such as the lack of 
major drug metabolizing enzymes or regeneration/compen-
satory mechanisms. Given that human DILI remains poorly 
predicted by animal models, due possibly to the polymor-
phic nature of the human liver, further investigations into 
such in vitro approaches with addition of drug metabolizing 
enzymes or use of more human-based systems may likely 
prove worthwhile in future studies.
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